Familial lecithin-cholesterol acyltransferase deficiency: Biochemical characteristics and molecular analysis of a new LCAT mutation in a Polish family


      Familial LCAT deficiency (FLD) is a rare genetic disorder associated with corneal opacities, anaemia and proteinuria with renal failure. Here we report detailed analyses on plasma lipids, lipoproteins, and the molecular defect in two siblings from a Polish family presenting classical symptoms of FLD and their family members with newly discovered Val309Met mutation in exon 6 of LCAT gene. Both patients displayed low total (2.19 and 2.94 mmol/l) and HDL-cholesterol concentrations (0.52 and 0.48 mmol/l), low percentage of cholesteryl esters (CE) (11.1 and 12%), and decreased apo AI and apo AII serum levels. Low LDL-cholesterol, apo B and Lp(a) levels, and increased oleate/linoleate ratios in CE could be of importance in the development of atherosclerosis in these patients with low HDL-cholesterol.
      LCAT activity was 10% of normal, α-LCAT activity was 0, and LCAT concentration was undetectable by immunoassay. Plasma CETP activity was at lower limits of normal.
      PCR and sequence analysis of DNA from the proband and affected brother revealed a novel G → A mutation in exon 6 of LCAT gene, which resulted in an amino acid substitution of valine for methionine (Val309Met). The proband and affected brother were both homozygous carriers, while the mother, siblings and children of patients were heterozygous carriers of a newly discovered mutation. This is the first LCAT mutation described in the Slavic population.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Barter P.J.
        • Rye K.A.
        Lecithin: cholesterol acyltransferase.
        in: Betteridge DJ. Ilingworth DR. Shepherd J. Lipoproteins in health and disease. Arnold, 1999
        • Liu M.
        • Bagdade J.D.
        • Subbaiah P.V.
        Specificity of lecithin:cholesterol acyltransferase and atherogenic risk: comparative studies on the plasma composition and in vitro synthesis of cholesteryl esters in 14 vertebrate species.
        J Lipid Res. 1995; 3: 1813-1824
        • Le Goff W.
        • Guerin M.
        • Chapman M.J.
        Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.
        Pharmacol Ther. 2004; 101: 17-38
        • Wu C.
        • Tsujita M.
        • Okumura–Noji K.
        • et al.
        Cholesteryl ester transfer protein expressed in lecithin cholesterol acyltransferase-deficient mice.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1347-1353
        • Santamarina Fojo S.
        • Lambert G.
        • Hoeg J.M.
        • Brewer Jr., H.B.
        Lecithin-cholesterol acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport and atherosclerosis.
        Current Opinion Lipidol. 2000; 11: 267-273
        • Kasid A.
        • Rhyne J.
        • Zeller K.
        • Pritchard H.
        • Miller M.
        A novel TC deletion resulting in Pro 260 Stop in the human LCAT gene is associated with a dominant effect on HDL-cholesterol.
        Atherosclerosis. 2001; 156: 127-132
        • Guerin M.
        • Dachet C.
        • Goulinet S.
        • et al.
        Familial lecithin:cholesterol acyltransferase deficiency: molecular analysis of compound heterozygote: LCAT (Arg 147 → Trp) and LCAT (Tyr 171 → Stop).
        Atherosclerosis. 1997; 131: 85-95
        • Chomczynski P.
        • Mackey K.
        • Drews R.
        • Wilfinger W.
        DNAzol: a reagent for the rapid isolation of genomic DNA.
        Biotechniques. 1997; 22: 550-553
        • Tichy J.
        • Dencker S.J.
        Separation of cholesterol esters. A comparison between paper and thin layer chromatography.
        J Chromatogr. 1968; 33: 262-266
        • Kahovcova J.
        • Otaviĉ R.
        A simple method for the quantitative analysis of phospholipids separated by thin-layer chromatography.
        J Chromatogr. 1969; 40: 90-96
        • Kostner G.M.
        • Ibovnik A.
        • Holzer H.
        • Grillhofer H.
        Preparation of stable fresh frozen primary lipoprotein—a [Lp (a)] standard.
        J Lipid Res. 1999; 40: 2255-2263
        • Kraft H.G.
        • Lingenhel A.
        • Bader G.
        • Kostner G.M.
        • Utermann G.
        The relative electrophoretic mobility of apo (a) isophorms depends on the gel system: proposal of a nomenclature for apo (a) phenotype.
        Atherosclerosis. 1996; 125: 53-61
        • Havel R.J.
        • Eder H.A.
        • Bragdon J.H.
        The distribution and chemical composition of ultracentifugally separated lipoproteins in human serum.
        J Clin Invest. 1955; 34: 1345-1353
        • Steyrer E.
        • Kostner G.
        Activation of lecithin cholesterol acyl-transferase by apolipoprotein D: comparison of proteoliposomes containing apolipoprotein D,A-I or C-1.
        Biochim Biophys Acta. 1988; 958: 484-491
        • Albers J.J.
        • Chen C.H.
        • Lacko A.G.
        Isolation, characterization and assay of lecithin: cholesterol acyltransferase.
        Methods Enzymol. 1986; 129: 763-783
        • Stokke K.T.
        • Norum N.R.
        Determination of lecithin:cholesterol acyltransferase in human blood plasma.
        Scand J Lab Invest. 1971; 22: 21-27
        • Kobori K.
        • Saito K.
        • Ito S.
        • Kotani K.
        • Manabe M.
        • Kanno T.
        A new enzyme-linked immunosorbent assay with two monoclonal antibodies to specific epitopes measures human lecithin-cholesterol acyltransferase.
        J Lipid Res. 2002; 43: 325-334
        • Argyropoulos G.
        • Jenkins A.
        • Klein R.L.
        • et al.
        Transmission of two novel mutations in a pedigree with familial lecithin:cholesterol acyltransferase deficiency: structure-function relationships and studies in a compound heterozygous proband.
        J Lipid Res. 1998; 39: 1870-1876
        • Teh E.M.
        • Chisholm J.W.
        • Dolphin P.J.
        • et al.
        Classical LCAT deficiency resulting from a novel homozygous dinucleotide deletion in exon 4.
        Atherosclerosis. 1999; 146: 141-151
        • Yang X.-P.
        • Inazu A.
        • Honjo A.
        • et al.
        Catalytically inactive lecithin:cholesterol acyltransferase (LCAT) caused by a Gly 30 to Ser mutation in a family with LCAT deficiency.
        J Lipid Res. 1997; 38: 585-591
        • Peelmann F.
        • Verschelde J.-L.
        • Vanloo B.
        • et al.
        Effects of natural mutations in lecithin:cholesterol acyltransferase on the enzyme structure and activity.
        J Lipid Res. 1999; 40: 59-69
        • Vaisman B.L.
        • Klein H.G.
        • Rouis M.
        • et al.
        Overexpression of human lecithin-cholesterol acyltransferase (LCAT) leads to hyperalphalipoproteinemia in transgenic mice.
        J Biol Chem. 1995; 270: 12269-12275
        • Steyrer E.
        • Durovic S.
        • Frank S.
        • et al.
        The role of lecithin:cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma.
        J Clin Invest. 1994; 94: 2330-2340
        • Nanjee M.N.
        • Stock S.J.
        • Cooke C.J.
        • et al.
        A novel LCAT mutation (Phe382 → Val) in a kindred with familial LCAT deficiency and defective apolipoprotein B-100.
        Atherosclerosis. 2003; 170: 105-113
        • Kingsbury K.J.
        • Stovold R.
        • Morgan D.M.
        • Brett C.G.
        The relationship between plasma cholesteryl polyunsaturated fatty acids, age and atherosclerosis.
        Postgrad Med J. 1969; 45: 591-601
        • Erkkila A.T.
        • Lehto S.
        • Pyorala K.
        Uusitupa MI. n-3 Fatty acids and 5-y risks of death and cardiovascular diseases events in patients with coronary artery disease.
        J Clin Nutr. 2002; 78: 65-71
        • Mehlum A.
        • Staels B.
        • Duverger N.
        • et al.
        Tissue specific expression of the human gene for lecithin:cholesterol acyltransferase in transgenic mice alters blood lipids, lipoproteins and lipases towards a less atherogenic profile.
        Eur J Biochem. 1995; 230: 567-575
        • Lynn E.G.
        • Siow Y.L.
        • Frohlich J.
        • Cheung G.T.
        O.K. Lipoprotein-X stimulates monocyte chemoattractant protein -1 expression in mesangial cells via nuclear factor-kappa B.
        Kidney Int. 2001; 60: 520-532
        • Lambert G.
        • Sakai N.
        • Vaisman B.L.
        • et al.
        Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesteol acyltransferase-deficient mice.
        J Biol Chem. 2001; 276: 15090-15098
        • Subbaiah P.V.
        • Liu M.
        Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction.
        J Biol Chem. 1993; 268: 20156-20163
        • Kriz W.
        Podocytes as a target for treatment with ACE inhibitors and/or angiotensin-receptor blockers.
        Kidney Int. 2004 Jan; 65: 333-334